The US company’s two simultaneous trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

Quantum Computing sees a 10% drop post-earnings. I downgraded QUBT stock to a sell due to overvaluation and speculative ...

Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.

Myles Garrett's plan to let his actions do the talking and make sure his teammates chalk his trade request up to the business ...

“…the index is likely completing an irregular expanded flat in EW terms: W>c>b>a. The ideal target is the 61.8% extension … at $19940, which the index is getting close to today … . If the index can ...

Liberty Latin America's new WiFi optimization & video services are poised to drive significant revenue and client growth. See ...

HENDERSON, Nev. — The Las Vegas Raiders agreed in principle to send a 2025 third-round pick (via the New York Jets) to the ...

Learn more about whether Belden Inc. or Celestica Inc. is a better investment based on AAII's A+ Investor grades, which ...

Senate Majority Leader Chuck Schumer has managed to do the impossible: unite almost the entire left (against him).

Donald Trump and his Office of Management and Budget Director Russell Vought plan to impound federal spending after Congress ...

Copyright © 2025 Bleacher Report, Inc. A Warner Bros. Discovery Company. All Rights Reserved.